Will Wegovy be added to Australia's PBS soon?

The Pharmaceutical Benefits Advisory Committee has recommended Wegovy's PBS listing for eligible adults with obesity and cardiovascular disease, with government price negotiations to follow.

Who will be eligible for subsidized Wegovy in Australia?

Eligibility requires adults with obesity and established cardiovascular disease, including those who have had a heart attack or stroke, and meet strict weight thresholds.

How much will Wegovy cost in Australia if subsidized?

If listed on the PBS, costs will significantly reduce, potentially aligning with the $25 maximum prescription price for PBS medicines.

Home / Health / Millions of Australians May Soon Access Subsidized Wegovy

Millions of Australians May Soon Access Subsidized Wegovy

12 Jan

•

Summary

Wegovy may soon be subsidized on Australia's PBS for eligible adults.
Strict criteria include cardiovascular disease and weight thresholds.
This aims to improve equity and reduce out-of-pocket costs for many.

Millions of Australians May Soon Access Subsidized Wegovy

The Australian government is preparing to subsidize the weight-loss medication Wegovy on the Pharmaceutical Benefits Scheme (PBS), potentially making it more accessible to millions. This decision follows a recommendation from the Pharmaceutical Benefits Advisory Committee for adults with obesity and established cardiovascular disease. Eligible individuals must have experienced a serious cardiovascular event and meet specific weight requirements.

Health Minister Mark Butler has indicated that price negotiations with the drug's manufacturer, Novo Nordisk, will commence. Currently, many Australians face significant out-of-pocket expenses, with costs potentially reaching $4,000 to $5,000 annually. Butler emphasized that improving access to Wegovy is a critical health and equity issue, as it suppresses appetite and aids significant weight loss.